Baricitinib, another FDA-approved JAKi, blocks interferon responses in Alzheimer’s disease [109] while the JAK2 inhibitor AZD1480 lessens neuroinflammation and neurodegeneration in Parkinson’s disease [110]. This evidence concerns the gene JAK2 and early-onset autosomal dominant Alzheimer disease.